Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection

An isolated antibody that binds Epstein Barr Virus (EBV) gp350 protein, comprising a variable heavy (VH) domain and a variable light (VL) domain, wherein:

• (a) the VH domain comprises the complementarity determining region 1 (CDR1), CDR2 and CDR3 sequences of SEQ ID NO:
• 3, SEQ ID NO:
• 4 and SEQ ID NO:
• 5, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 8, SEQ ID NO:
• 9 and SEQ ID NO:
• 10, respectively;
• (b) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 13, SEQ ID NO:
• 14 and SEQ ID NO:
• 15, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 18, SEQ ID NO:
• 19 and SEQ ID NO:
• 20, respectively;
• (c) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 23, SEQ ID NO:
• 24 and SEQ ID NO:
• 25, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 28, SEQ ID NO:
• 29 and SEQ ID NO:
• 30, respectively;
• (d) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 33, SEQ ID NO:
• 34 and SEQ ID NO:
• 35, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 38, SEQ ID NO:
• 39 and SEQ ID NO:
• 40, respectively;
• (e) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 43, SEQ ID NO:
• 44 and SEQ ID NO:
• 45, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 48, SEQ ID NO:
• 49 and SEQ ID NO:
• 50, respectively;
• (f) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 163, SEQ ID NO:
• 164 and SEQ ID NO:
• 165, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 168, SEQ ID NO:
• 169 and SEQ ID NO:
• 170, respectively, wherein the antibody is an engineered antibody;
• (g) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 173, SEQ ID NO:
• 174 and SEQ ID NO:
• 175, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 178, SEQ ID NO:
• 179 and SEQ ID NO:
• 180, respectively, wherein the antibody is an engineered antibody;
• (h) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 183, SEQ ID NO:
• 184 and SEQ ID NO:
• 185, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 188, SEQ ID NO:
• 189 and SEQ ID NO:
• 190, respectively, wherein the antibody is an engineered antibody;
• (i) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 193, SEQ ID NO:
• 194 and SEQ ID NO:
• 195, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 198, SEQ ID NO:
• 199 and SEQ ID NO:
• 200, respectively, wherein the antibody is an engineered antibody;
• (j) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 203, SEQ ID NO:
• 204 and SEQ ID NO:
• 205, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 208, SEQ ID NO:
• 209 and SEQ ID NO:
• 210, respectively, wherein the antibody is an engineered antibody;
• (k) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 213, SEQ ID NO:
• 214 and SEQ ID NO:
• 215, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 218, SEQ ID NO:
• 219 and SEQ ID NO:
• 220, respectively, wherein the antibody is an engineered antibody;
• (l) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 223, SEQ ID NO:
• 224 and SEQ ID NO:
• 225, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 228, SEQ ID NO:
• 229 and SEQ ID NO:
• 230, respectively, wherein the antibody is an engineered antibody;
• (m) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 233, SEQ ID NO:
• 234 and SEQ ID NO:
• 235, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 238, SEQ ID NO:
• 239 and SEQ ID NO:
• 240, respectively, wherein the antibody is an engineered antibody;
• (n) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 243, SEQ ID NO:
• 244 and SEQ ID NO:
• 245, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 248, SEQ ID NO:
• 249 and SEQ ID NO:
• 250, respectively, wherein the antibody is an engineered antibody;
• (o) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 253, SEQ ID NO:
• 254 and SEQ ID NO:
• 255, respectively, and the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 258, SEQ ID NO:
• 259 and SEQ ID NO:
• 260, respectively, wherein the antibody is an engineered antibody;
• (p) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 263, SEQ ID NO:
• 264 and SEQ ID NO:
• 265, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 268, SEQ ID NO:
• 269 and SEQ ID NO:
• 270, respectively, wherein the antibody is an engineered antibody;
• (q) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 273, SEQ ID NO:
• 274 and SEQ ID NO:
• 275, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 278, SEQ ID NO:
• 279 and SEQ ID NO:
• 280, respectively, wherein the antibody is an engineered antibody;
• (r) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 283, SEQ ID NO:
• 284 and SEQ ID NO:
• 285, respectively, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
• 288, SEQ ID NO:
• 289 and SEQ ID NO:
• 290, respectively, wherein the antibody is an engineered antibody.